Addex Therapeutics (NASDAQ:ADXN) Raised to Buy at HC Wainwright

HC Wainwright upgraded shares of Addex Therapeutics (NASDAQ:ADXN) from a neutral rating to a buy rating in a report published on Wednesday morning, MarketBeat Ratings reports. The brokerage currently has $30.00 price objective on the stock. HC Wainwright also issued estimates for Addex Therapeutics’ Q2 2024 earnings at ($0.07) EPS, Q3 2024 earnings at ($0.07) EPS, Q4 2024 earnings at ($0.07) EPS and FY2025 earnings at ($0.34) EPS.

Addex Therapeutics Stock Down 1.3 %

NASDAQ:ADXN opened at $7.90 on Wednesday. Addex Therapeutics has a fifty-two week low of $5.00 and a fifty-two week high of $27.90. The stock has a market cap of $8.37 million, a PE ratio of -0.46 and a beta of 1.77. The firm’s fifty day simple moving average is $8.30 and its 200-day simple moving average is $10.79.

Addex Therapeutics (NASDAQ:ADXN) last posted its quarterly earnings results on Thursday, June 6th. The company reported ($1.37) earnings per share for the quarter. Addex Therapeutics had a negative return on equity of 364.24% and a negative net margin of 818.50%. The company had revenue of $0.27 million for the quarter. Equities analysts anticipate that Addex Therapeutics will post -11.8 earnings per share for the current year.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.